CannaTech has announced registration for its 3rd annual cannabis summit to take place in Tel Aviv, Israel, March 20-22, 2017.
CannaTech will showcase the most current science, data and industry trends in medical marijuana today, highlighting new technologies, R&D and innovations that will guide the future of this multi-billion-dollar industry.
Presentations will be given by international industry leaders from numerous disciplines, including science, research, finance, ag tech, government policy and regulation.
Early bird tickets are on sale until December 18 and cost $420 for the two-day event. There is a separate fee for a third day of exclusive VIP travel touring. Early bird tickets can be purchased online at the event site, http://www.canna-tech.co.
Confirmed speakers include renowned Professor of Pharmacology, Psychiatry and Behavioral Sciences, Dr. Nephi Stella of the University of Washington, whose lab focuses on the role of cannabis and cutting edge neuroscience, and Cristina Sanchez, PhD, a molecular biologist at Compultense University in Madrid Spain, who leads groundbreaking research in the role of cannabis and cancer treatment. They will be joined by many of Israel’s industry leaders among them Dr. David Meiri, leading cannabis researcher at the Technion, and iCAN: israel-cannabis CEO Saul Kaye.
“CannaTech is a global ecosystem that allows participants to meet and collaborate with the upper echelon of this industry,” said Kaye. “Most other conferences focus on what’s happening now in cannabis, CannaTech is the place to see what is next in cannabis.”
Kalytera Therapeutics are sponsors of CannaTech 2017. Kalytera is advancing a portfolio of non-psychoactive cannabinoid and endocannabinoid-like medicines. Dr. Raphael Mechoulam, the most influential figure in cannabis medicine to date and former CannaTech keynote speaker, co-chairs their scientific leadership team.
To learn more visit http://www.canna-tech.co or email .